2012-11-14T14:51:55-06:00 2011-12-31 911194016 CLARK NUBER PS 10900 NE 4TH STREET SUITE 1700 BELLEVUE WA 98004 990 2011-01-01 911608978 INFECTIOUS DISEASE RESEARCH INSTITUTE INFE 2065186267 1124 COLUMBIA STREET NO 400 SEATTLE WA 98104 CURTIS MALLOY 2065186267 2012-11-14 1 JANE M SEARING P00000565 4254544919 2012-11-14 2011 2016-02-24 21:20:13Z CURTIS MALLOY 1124 COLUMBIA STREET NO 400 SEATTLE WA 98104 18071715 0 X WWW.IDRI.ORG X 1993 WA DEVELOP VACCINES, DIAGNOSTICS & DRUGS TO PREVENT, DETECT & TREAT INFECTIOUS DISEASES OF POVERTY. 10 8 132 8 643380 0 11561223 14410786 2373753 2463111 18026 53600 606808 288928 14559810 17216425 0 0 0 0 7743408 9319146 0 0 158660 13860619 13965812 21604027 23284958 -7044217 -6068533 48731045 42428324 3825404 3595070 44905641 38833254 X DEVELOP VACCINES, DIAGNOSTICS AND NOVEL DRUGS TO PREVENT, DETECT AND TREAT INFECTIOUS DISEASES OF POVERTY. 0 0 7904636 1247481 VACCINE RESEARCH - VACCINES ARE COMPOSED OF SEVERAL COMPONENTS: (A) ANTIGENS THAT STIMULATE THE IMMUNE SYSTEM TO COMBAT A PARTICULAR INFECTIOUS DISEASE AND (B) ADJUVANTS, SUBSTANCES THAT ENHANCE THE ABILITY OF ANTIGENS TO STIMULATE THE BODY'S IMMUNE RESPONSE. PUT ANOTHER WAY, ANTIGENS DETERMINE THE SPECIFICITY OF THE IMMUNE RESPONSE (E.G., FOR INFLUENZA OR TETANUS) WHEREAS ADJUVANTS AFFECT THE MAGNITUDE OF THE BODY'S IMMUNE RESPONSE.IDRI'S SCIENTISTS ARE USING THE LATEST TECHNIQUES TO IDENTIFY THE BEST ANTIGENS FOR NEW VACCINES TO COMBAT DISEASES THAT IMPACT GLOBAL HEALTH. IDRI'S CANDIDATE VACCINE FOR LEISHMANIASIS IS CURRENTLY IN CLINICAL TESTING AND VACCINES FOR TUBERCULOSIS AND LEPROSY ARE POISED TO START CLINICAL TESTING. 5474357 102025 ADJUVANT RESEARCH - AN IMPORTANT AREA OF RESEARCH FOR IDRI IS IMPROVING ADJUVANTS AND HOW THEY ARE COMBINED WITH ANTIGENS TO IMPROVE VACCINES. BETTER ADJUVANTS CAN INCREASE AND BROADEN THE IMMUNE RESPONSE TO AN ANTIGEN, AS WELL AS REDUCE THE AMOUNT OF ANTIGEN NECESSARY FOR A GOOD RESPONSE. THIS LAST CHARACTERISTIC CAN MAKE OUR VACCINE STOCKS GO FURTHER AND POTENTIALLY REDUCE THE COST. IDRI IS COLLABORATING WITH PARTNERS ALL OVER THE WORLD TO IMPROVE VACCINES FOR ADDITIONAL CHALLENGING DISEASES SUCH AS MALARIA AND PANDEMIC INFLUENZA. 1968418 787355 TUBERCULOSIS DRUG DISCOVERY - IN ADDITION TO WORKING ON BETTER DIAGNOSTIC TESTS AND VACCINES FOR TUBERCULOSIS (TB), IDRI HAS AN EARLY DISCOVERY PROGRAM TO IDENTIFY NEW CHEMICAL COMPOUNDS THAT ARE CANDIDATES TO TREAT TB. THERE IS AN URGENT NEED FOR NEW TYPES OF TB DRUGS; THE ONES CURRENTLY USED WERE DEVELOPED OVER 40 YEARS AGO AND WE ARE FACED WITH AN INCREASING THREAT FROM BACTERIA THAT ARE RESISTANT TO MANY OF THESE DRUGS. THE DRUG DISCOVERY GROUP COMBINES THE SKILLS OF MICROBIOLOGISTS, CHEMISTS, AND MOLECULAR BIOLOGISTS AND COLLABORATES WITH PHARMACEUTICAL COMPANIES AND OTHER RESEARCH INSTITUTIONS TO MAXIMIZE OUR CHANCE OF SUCCESS. 101031 174693 MANUFACTURING - ONCE A VACCINE CANDIDATE HAS BEEN IDENTIFIED IN THE RESEARCH LAB, THE NEXT CHALLENGE IS TO APPLY THAT DISCOVERY TO THE CLINICAL SETTING. A NECESSARY PART OF THIS TRANSITION IS TO PRODUCE VACCINES UNDER CONTROLLED CONDITIONS SO THAT THEY ARE SUITABLE FOR USE IN HUMAN STUDIES. IDRI HAS DEVELOPED THE TYPE OF MANUFACTURING CAPABILITY REQUIRED TO MOVE A VACCINE FROM LATE STAGE RESEARCH TO EARLY CLINICAL STUDIES. 951621 151557 OTHER ACTIVITIES - IDRI'S CLINICAL GROUP DESIGNS AND CONDUCTS EARLY STAGE CLINICAL TRIALS TO TEST THE VACCINE CANDIDATES IDENTIFIED BY IDRI SCIENTISTS OR COLLABORATORS. THROUGH OUR NETWORK OF GLOBAL CONNECTIONS, THE CLINICAL TEAM IS ABLE TO LAUNCH CLINICAL TRIALS ALMOST ANYWHERE IN THE WORLD. 1052652 326250 16400063 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 41 0 1 132 1 1 1 0 0 0 0 0 0 0 0 0 X 10 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 WA X THERESE COAD AND PATRICIA MIELE 2065186267 1124 COLUMBIA STREET SUITE 400 SEATTLE WA 98104 H STEWART PARKER 50.00 X X 296195 0 9413 ERIC EASOM 2.00 X X 0 0 0 DAVID MAKI JD 2.00 X X 0 0 0 DAVID WEBSTER 2.00 X X 0 0 0 STEVEN REED PHD 20.00 X X 119511 0 0 CHRISTOPHER EARL PHD 2.00 X 0 0 0 CYNTHIA HEALY PHD 2.00 X 0 0 0 CHRIS HENTSCHEL PHD 2.00 X 0 0 0 DAVID PERRY 2.00 X 0 0 0 FRANKLYN PRENDERGAST MD 2.00 X 0 0 0 CURTIS MALLOY 50.00 X 186844 0 19393 KAREN KINCH 50.00 X 120651 0 13890 ERIK IVERSON JD LLM 40.00 X 62457 0 4333 ANNA MARIE BECKMANN 40.00 X 147153 0 20332 DARRICK CARTER 40.00 X 144902 0 17649 RHEA COLER 40.00 X 146779 0 3686 FRANCO PIAZZA 40.00 X 235268 0 5406 WINSTON WICOMB 40.00 X 139619 0 19942 1599379 0 114044 20 0 1 0 BIOANALYTICAL SYSTEMS INC 10424 MIDDLE MOUNT VERNON RD MOUNT VERNON IN 46720 RESEARCH 581430 ST GEORGE'S UNIVERSITY OF LONDON CRANMER TERRACE LONDON UK RESEARCH 292466 CFO SELECTIONS LLC 14432 SE EASTGATE WAY 400 BELLEVUE WA 98007 HUMAN RESOURCES 170844 SEED IP LAW GROUP LLC 701 FIFTH AVENUE SUITE 5400 SEATTLE WA 981047092 LEGAL SERVICES 156088 UNIVERSITY OF LAUSANNE DORGINY 1015 021 692 11 11 LAUSANNE SZ RESEARCH 154064 10 8427006 5983780 14410786 CONTRACT REVENUE 541700 1606419 1606419 VIVARIUM INCOME 541700 613042 613042 LICENSING REVENUE 541700 100000 100000 RESEARCH REVENUE 541700 60108 60108 IT SERVICES 541700 3538 3538 80004 80004 2463111 53600 53600 427807 427807 675906 26800 855290 0 -179384 26800 -152584 26800 -179384 REIMBURSEMENTS 900099 12502 12502 REFUNDS 900099 1203 1203 13705 17216425 1846531 643380 315728 832687 774399 58288 6810661 6079010 664160 67491 87128 86926 202 973157 888559 78746 5852 615513 609895 5618 306339 238075 68264 222304 222304 1546 1546 86476 17872 67181 1423 61352 6304 55048 177153 41727 135426 194301 47974 146327 571647 571647 2394245 515844 1867147 11254 271820 199775 72045 54986 9054 45932 934825 926293 8532 86717 21256 65461 LAB SUPPLIES 3709392 3654260 55132 SUBCONTRACTS 2322990 2297811 25179 CONTRACTED SERVICES 2040148 2040114 34 REPAIRS & MAINTENANCE 329192 242148 87044 200379 100280 100099 23284958 16400063 6726235 158660 1012591 1814379 19270320 21406644 25590537 16776863 605496 373927 132504 101879 5852860 3901151 2119597 1951709 250 0 2673 48731045 42428324 2090001 2312315 1363900 1104589 371503 178166 3825404 3595070 X 3039070 2908320 41866571 35924934 44905641 38833254 48731045 42428324 X -6068533 -3854 X 0 1 1 X 1 1 X UNIVERSIDAD CENTRAL DE VENEZUELA CARACAS VE UNIVERSITY OF KHARTOUM KHARTOUM SU CASE WESTERN RESERVE UNIVERSITY CLEVELAND OH BANARAS HINDU UNIVERSITY VARANASI IN UNIVERSIDAD PERUANA CAGETANO HEREDIA LIMA PE RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 1546 0 0 1546 0 EXPLANATION OF LOBBYING ACTIVITIES: PART II-B, LINE 1: AMOUNT PAID DIRECTLY TO LOBBYIST FOR ONE MONTH OF SERVICE IN 2011. 503204 458736 44468 5349656 3442415 1907241 1951709 DEFERRED RENT 178166 178166 17216425 23284958 -6068533 -3854 -3854 -6072387 16820308 -3854 -571647 -575501 17395809 -179384 -179384 17216425 22892695 179384 179384 22713311 571647 571647 23284958 PART XII, LINE 2D - OTHER ADJUSTMENTS: ROYALTY EXPENSES NETTED WITH ROYALTY INCOME FOR FS PURPOSES -571,647. PART XII, LINE 4B - OTHER ADJUSTMENTS: NET RENTAL INCOME NOT INCLUDED IN REVENUES ON FINANCIALS -179,384. PART XIII, LINE 2D - OTHER ADJUSTMENTS: NET RENTAL INCOME REPORTED WITH REVENUES ON TAX RETURN 179,384. PART XIII, LINE 4B - OTHER ADJUSTMENTS: ROYALTY EXPENSES NETTED WITH ROYALTY INCOME FOR FS PURPOSES 571,647. EUROPE (INCLUDING ICELAND & GREENLAND) - 0 0 PROGRAM SERVICES RESEARCH 972019 SOUTH AMERICA 0 0 PROGRAM SERVICES RESEARCH 181363 NORTH AMERICA 0 0 PROGRAM SERVICES RESEARCH 50210 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES RESEARCH 74913 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES RESEARCH 130029 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES RESEARCH 274081 0 0 0 0 0 0 1682615 0 1682615 0 0 0 0 0 0 X X X 0 0 0 0 0 0 0 0 0 H STEWART PARKER 296195 0 0 0 0 0 5225 0 4188 0 305608 0 0 0 CURTIS MALLOY 186844 0 0 0 0 0 2062 0 17331 0 206237 0 0 0 ANNA MARIE BECKMANN 147153 0 0 0 0 0 3001 0 17331 0 167485 0 0 0 DARRICK CARTER 144902 0 0 0 0 0 318 0 17331 0 162551 0 0 0 RHEA COLER 146779 0 0 0 0 0 2986 0 700 0 150465 0 0 0 FRANCO PIAZZA 235268 0 0 0 0 0 4706 0 700 0 240674 0 0 0 WINSTON WICOMB 139619 0 0 0 0 0 2611 0 17331 0 159561 0 0 0 IMMUNE DESIGN CORPORATION SEE PART V 2162162 SEE PART V 0 SCH. L, PART IV BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS: (A) NAME OF PERSON: IMMUNE DESIGN CORPORATION(B) RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION: BOARD MEMBER STEVEN REED IS THE VICE PRESIDENT FOR IMMUNE DESIGN CORP.(D) DESCRIPTION OF TRANSACTION: SUBCONTRACTOR REVENUES FORM 990, PART 1, LINE 6: THERE WERE EIGHT VOLUNTEER BOARD MEMBERS DURING THE YEAR. BOARD MEMBERS PARTICIPATE IN STRATEGIC PLANNING, EXECUTIVE LEADERSHIP RECRUITMENT AND SELECTION, INTELLECTUAL PROPERTY STRATEGY, AND IDENTIFICATION OF INSTITUTIONAL LIABILITY. THEY COME FROM A VARIETY OF BACKGROUNDS AND DEMONSTRATE FINANCIAL EXPERTISE, REAL ESTATE LEASING/PURCHASING EXPERTISE, BIO-MEDICAL NOT-FOR-PROFIT EXPERTISE, AND AN UNDERSTANDING OF BUSINESS AND BIOTECH LICENSING. FORM 990, PART VI, SECTION B, LINE 11 A DRAFT COPY OF THE FORM 990 AND FORM 990-T WILL BE PRESENTED TO THE AUDIT COMMITTEE FOR REVIEW. THEN THE AUDIT COMMITTEE WILL REVIEW AND APPROVE THE FORM 990 AND 990-T ON BEHALF OF THE IDRI BOARD OF DIRECTORS. ALL BOARD MEMBERS WILL RECEIVE A COPY OF THE FORM 990 AND 990-T PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C EACH JANUARY, MEMBERS OF THE BOARD OF DIRECTORS ARE GIVEN A COPY OF THE "CONFLICT OF INTEREST POLICY". THEY ARE REQUIRED TO FILL IT OUT AND RETURN IT BY THE FIRST BOARD MEETING - USUALLY SOMETIME IN THE FIRST QUARTER. THE SENIOR VICE PRESIDENT OF OPERATIONS AND GENERAL COUNSEL REVIEWS THE QUESTIONNAIRES AND SUMMARIZES THE RESULTS. THE RESULTS ARE COMMUNICATED TO THE BOARD OF DIRECTORS. TO THE EXTENT THAT THERE ARE ANY CONFLICTS, THE MEMBER IS RECUSED FROM ANY DECISION MAKING THAT WOULD INCLUDE THE CONFLICT. WHEN THE OCCASION ARISES, THOSE MEMBERS ALSO REMIND THE GROUP (MANAGEMENT TEAM OR BOARD) THAT THERE IS A POTENTIAL CONFLICT WHEN SPECIFIC DISCUSSION TOPICS ARISE. FORM 990, PART VI, SECTION B, LINE 15 THE CEO SIGNED AN INITIAL CONTRACT IN 2011 BUT WILL RECEIVE ANNUAL EVALUATIONS AND REVIEW BY THE BOARD. THE BOARD CHAIR ALSO DOES AN ANNUAL REVIEW OF ALL OTHER OFFICERS AND KEY EMPLOYEES AND WORKS WITH THE HUMAN RESOURCES DEPARTMENT TO DETERMINE IF THE COMPENSATION IS ADEQUATE. IF AN ADJUSTMENT IS DEEMED NECESSARY, THE BOARD CHAIR CONVENES THE COMPENSATION COMMITTEE AND THE ADJUSTMENT IS ADDRESSED. THE BOARD CHAIR REPORTS BACK TO THE HUMAN RESOURCES DEPARTMENT WHO FOLLOWS THROUGH WITH THE COMMITTEE'S RECOMMENDATION. FORM 990, PART VI, SECTION C, LINE 19 WHEN IDRI RECEIVES REQUESTS TO SHARE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS, THE PRESIDENT REVIEWS THE REQUEST AND, IF WARRANTED, DISCUSSES THE REQUEST WITH THE IDRI FINANCE COMMITTEE OR OTHER RELEVANT GOVERNING COMMITTEES. SUCH REQUESTS ARE TAKEN VERY SERIOUSLY IN LIGHT OF OUR BELIEF THAT NON-PROFIT ORGANIZATIONS SHOULD BE AS TRANSPARENT AS POSSIBLE. CHANGES IN NET ASSETS OR FUND BALANCES: FORM 990, PART XI, LINE 5: NET UNREALIZED GAINS (LOSSES) ON INVESTMENTS -3,854. TOTAL TO FORM 990, PART XI, LINE 5: -3,854.